- Home
- VRCA vs BTAI Comparison
VRCA vs BTAI Comparison
Compare VRCA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | BTAI |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 49.2M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VRCA | BTAI |
|---|---|---|
| Price | $8.27 | $2.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 387.1K | ★ 629.9K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,829,000.00 | $752,000.00 |
| Revenue This Year | $373.65 | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $1.17 |
| 52 Week High | $10.50 | $9.26 |
Technical Indicators
Market Signals| Indicator | VRCA | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 53.29 |
| Support Level | $6.26 | $1.82 |
| Resistance Level | $9.78 | $2.28 |
| Average True Range (ATR) | 1.16 | 0.17 |
| MACD | 0.30 | 0.05 |
| Stochastic Oscillator | 74.02 | 67.28 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.